Journal article
Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the field randomised trial
R Scott, M Donoghoe, GF Watts, R O'Brien, C Pardy, MR Taskinen, TME Davis, PG Colman, P Manning, G Fulcher, AC Keech
Cardiovascular Diabetology | BMC | Published : 2011
Abstract
Background: Patients with the metabolic syndrome are more likely to develop type 2 diabetes and may have an increased risk of cardiovascular disease (CVD) events.We aimed to establish whether CVD event rates were influenced by the metabolic syndrome as defined by the World Health Organisation (WHO), the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) and the International Diabetes Federation (IDF) and to determine which component(s) of the metabolic syndrome (MS) conferred the highest cardiovascular risk in in 4900 patients with type 2 diabetes allocated to placebo in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial.Research design a..
View full abstractGrants
Funding Acknowledgements
The FIELD study was supported by a grant from Laboratoires Fournier SA, Dijon, France (now part of Abbott) and the National Health and Medical Research Council (NHMRC) of Australia, and was coordinated independently by the NHMRC Clinical Trials Centre, University of Sydney. The authors thank Rhana Pike from the NHMRC Clinical Trials Centre, for assistance with the manuscript.